Tokyo - Delayed Quote JPY

M3, Inc. (2413.T)

1,902.50

-2.00

(-0.11%)

At close: 3:30:00 PM GMT+9

MEDIROM Healthcare Technology‘s Subsidiary, MEDIROM MOTHER Labs, Raises an Aggregate Total of JPY260.3 Million in its Series A Financing Round

Pre-Money Valuation of JPY9 Billion is Approximately Multiples of Current Parent Company Market Capitalization.Strategic Investors Further Validation of Technology and Growth Potential.Further Commercialization with Recent 25,000 Unit Order from B2B Sales Channel. TOKYO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) announces that its subsidiary MEDIROM MOTHER Labs Inc. raised to date an aggregate total of 260.3 million yen (approximtaely USD $ [1.7] millio

GlobeNewswire 4 months ago

EEAEF

MRM

MTHRF
M3 Group Joins MEDIROM Mother Labs’ Series A Financing Round at JPY9 Billion (as of December 1, 2024, approximately USD $59,000,000) Pre-Money Valuation

TOKYO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“MEDIROM”) announces that M3, Inc. (TOKYO PRIME: 2413), or an affiliate within the M3 group, is participating in the Series A equity financing round of MEDIROM MOTHER Labs Inc., a subsidiary of MEDIROM. NFES Technologies Inc. is the lead investor of the Series A financing round at a pre-money valuation of JPY9 billion. Additional information is available here: https://medirom.co.jp/en/ir/20240824/6148%09

GlobeNewswire 4 months ago

MTHRF

MTHRY

MRM

Performance Overview

Return	2413.T	Nikkei 225 (^N225)
YTD	+37.84%	-5.99%
1-Year	+13.97%	-1.50%
3-Year	-49.69%	+42.49%